A5103190307- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Silicon Carbide Semiconductor Technologies
- Advancements in Semiconductor Devices and Circuit Design
- Childhood Cancer Survivors' Quality of Life
- Toxoplasma gondii Research Studies
- Autopsy Techniques and Outcomes
- Pediatric health and respiratory diseases
- Neonatal and fetal brain pathology
- Clostridium difficile and Clostridium perfringens research
- Viral-associated cancers and disorders
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Neonatal Respiratory Health Research
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
- Mesenchymal stem cell research
- Cytomegalovirus and herpesvirus research
- Lymphoma Diagnosis and Treatment
Bambino Gesù Children's Hospital
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2023
Ospedale Santa Maria della Misericordia di Udine
2022
University of Udine
2021
Azienda Unità Sanitaria Locale di Ferrara
2020
University of Ferrara
2017
Reconstitution of T cells after transplantation is a determinant the long-term success procedure, and correlation with cell recovery cytomegalovirus reactivation disease well known. We evaluated 110 patients who underwent transplantation: 55 received pre-emptive antiviral treatment, in other patients, prophylaxis letermovir was employed. A progressive statistically significant difference reconstitution between 2 groups observed, starting from day +60 faster group. Moreover, higher incidence...
Background: Cryopreservation of PBSC for allogenic hematopoietic stem cell transplantation (allo-HSCT) was implemented due to the current Coronavirus 2019 pandemic. The impact match unrelated donor (MUD) graft freezing on outcome allo-HSCT in terms hematological recovery, versus host disease (GVHD), and survival are still controversial. Methods: In this study, we compared composition, clinical characteristics, 31 from MUD cryopreserved (Cryo Group) with 23 matched-pair fresh (Fresh performed...
Blinatumomab has remarkable efficacy in patients with relapsed/refractory (r/r) or measurable residual disease (MRD)-positive B-cell acute lymphoblastic leukemia (B-ALL). In many patients, blinatumomab treatment is followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, the influence of on HSCT outcomes children and young adults (YA) remains to be fully elucidated. We conducted a single-center, retrospective analysis given as last before HSCT. Seventy-eight pediatric...
Patients who undergo hematopoietic stem cell transplants (HSCT) are at major risk of C. difficile (CD) infection (CDI), the most common cause nosocomial diarrhea. We conducted a retrospective study, which enrolled 481 patients underwent autologous (220) or allogeneic HSCT (261) in 5-year period, with aim identifying incidence, factors and outcome CDI between start conditioning 100 days after HSCT. The overall cumulative incidence based upon clinical evidence was 5.4% (95% CI, 3.7% to 7.8%),...
Follicular lymphoma (FL) is an indolent hematological disease, often responsive to the first line of treatment, but characterized by repeated relapses. The therapeutic algorithm for relapsed/refractory FL patients comprises phosphatidylinositol 3-kinase inhibitors. Idelalisib showed anticancer activity, while inducing a significant rate toxicities. Since evidence in literature on its use normal clinical practice scarce, retrospective multicenter study was conducted evaluate effectiveness and...
Mucosal-associated invariant T (MAIT) cells are innate-like implicated in the response to fungal and bacterial infections. Their contribution restoring T-cell immunity influencing hematopoietic stem cell transplant (HSCT) outcomes remains poorly understood. We retrospectively studied MAIT-cell recovery 145 consecutive children young adults with hematologic malignancies undergoing allogeneic (allo)-HSCT between April 2019 May 2022, from unrelated matched donor (MUD, N=52), standard...